Immunic (IMUX) Other Accumulated Expenses (2013 - 2026)

Immunic has disclosed Other Accumulated Expenses across 14 years of filings, most recently posting $4.9 million for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $4.9 million, up 280.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.9 million (up 280.8% YoY), and the FY2025 annual result was $1.8 million, up 29.59% from the prior year.
• Other Accumulated Expenses came in at $4.9 million for Q1 2026 at Immunic, up from $1.8 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $4.9 million in Q1 2026 to a low of $544000.0 in Q2 2022.
• The 5-year median for Other Accumulated Expenses is $966000.0 (2023), against an average of $1.3 million.
• Across the five-year window, Other Accumulated Expenses slumped 86.83% in 2022 and soared 280.8% in 2026, its largest moves.
• Immunic's Other Accumulated Expenses stood at $810000.0 in 2022, then grew by 19.26% to $966000.0 in 2023, then soared by 46.58% to $1.4 million in 2024, then grew by 29.59% to $1.8 million in 2025, then jumped by 168.12% to $4.9 million in 2026.
• The last three Other Accumulated Expenses figures came in at $4.9 million (Q1 2026), $1.8 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.